Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial.

ABSTRACT:

Background

Metabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.

Aim

To evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.

Methods

This was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All

SUBMITTER: da Ponte Neto AM 

PROVIDER: S-EPMC10353513 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature